COL18A1 and non-small cell lung carcinoma: The administration of a novel recombinant endostatin produced in Escherichia coli (EndostarTM) in combination with chemotherapy in advanced non-small-cell lung cancer significantly increased response rates and time to progression when compared to chemotherapy alone (Sun et al, 2005).